Ardelyx bowel drug succeeds in mid-stage trial

(Reuters) - Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared with a placebo in a mid-stage study involving 371 patients.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Conclusions: Stool microbial diversity and composition are linked to daily extraintestinal symptoms, stool consistency, and QOL in women with IBS.
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: ALIMENTARY TRACT: Original Articles Source Type: research
Authors: Imran A, Whitehead WE, Palsson OS, Törnblom H, Simrén M Abstract Introduction: Chronic constipation is highly prevalent, affecting between 10% and 15% of the population. The Rome IV criteria categorizes disorders of chronic constipation into four subtypes: (a) functional constipation, (b) irritable bowel syndrome with constipation, (c) opioid-induced constipation, and (d) functional defecation disorders, including inadequate defecatory propulsion and dyssynergic defecation. The initial management approach for these disorders is similar, focusing on diet, lifestyle and the use of standard over-t...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Conditions:   Irritable Bowel;   Irritable Bowel Syndrome;   Irritable Bowel Syndrome With Diarrhea;   Irritable Bowel Syndrome Mixed;   Irritable Bowel Syndrome With Constipation;   Irritable Bowel Syndrome Without Diarrhea;   Irritable Bowel Syndrome Aggravated;   Irritable Bowel Syndrome Characterized by Constipation;   Irritable Bowel Syndrome Characterised by Alternating Bowel Habit Intervention:   Other: No intervention Sponsor:   ProgenaBiome Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Masuy I, Pannemans J, Tack J Abstract Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders (FGIDs) encountered in clinical practice. In the absence of an accurate biomarker for the disorder, IBS is mainly diagnosed based symptomology using the Rome criteria. Due to the heterogeneity of the disorder, finding the correct treatment option is often challenging. In general, lifestyle and dietary changes, including the low-FODMAP of gluten-free diet, are the first-in-line treatment for all patients. Issues with dietary changes are the strict elimination of multiple food ...
Source: Minerva Gastroenterologica e Dietologica - Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research
Conclusion: Functional diarrhea was associated with hemodynamic indices of sympathetic activation, supporting a possible role of the autonomic nervous system in diarrhea. PMID: 31791149 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Hydrogen formed by small intestinal bacterial overgrowth in patients with non-constipated irritable bowel syndrome has an inverse relationship with obesity. However, the effect of eradicating small intestinal hydrogen-producing bacterial overgrowth on the body weight of these patients has not yet been reported. The aim of this study was to investigate body weight changes after eradicating small intestinal bacterial overgrowth with rifaximin treatment in patients with non-constipated irritable bowel syndrome. We reviewed the charts of patients with non-constipated irritable bowel syndrome who showed abdominal symptoms with...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Many factors can cause colon pain, including constipation, diarrhea, irritable bowel syndrome, and colorectal cancer. Learn more about the causes of colon pain and their treatment options here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news
Conditions:   Irritable Bowel Syndrome With Constipation;   Functional Constipation Interventions:   Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers);   Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers): Sponsors:   Allergan;   Ironwood Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Constipation | Health | Irritable Bowel Syndrome | Study